$PHAS Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in PhaseBio Pharmaceuticals Inc.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in PhaseBio Pharmaceuticals Inc. Get notifications about new insider transactions in PhaseBio Pharmaceuticals Inc for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | S | 0.00 | 18 | 0 | 34,968 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | M | 0.00 | 710 | 0 | 34,986 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | M | 0.12 | 710 | 85 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | S | 0.00 | 170 | 0 | 347,250 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | M | 0.00 | 7,053 | 0 | 347,420 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | M | 0.12 | 7,053 | 846 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Buy | P | 5.00 | 6,041 | 30,205 | 281,096 | 275.1 K to 281.1 K (+2.20 %) |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Buy | C | 0.00 | 275,055 | 0 | 275,055 | 0 to 275.1 K |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Buy | P | 5.00 | 1,277 | 6,385 | 59,429 | 58.2 K to 59.4 K (+2.20 %) |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Buy | C | 0.00 | 58,152 | 0 | 58,152 | 0 to 58.2 K |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Buy | P | 5.00 | 12,682 | 63,410 | 590,168 | 577.5 K to 590.2 K (+2.20 %) |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Buy | C | 0.00 | 577,486 | 0 | 577,486 | 0 to 577.5 K |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 226,061 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 24,709 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 272,107 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 40,420 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 13,558 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 149,320 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 94,874 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 1,044,764 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 13,609 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 174,699 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 4,846 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 3,862 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 42,530 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 52,690 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | S | 0.00 | 994 | 0 | 40,420 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | M | 0.00 | 41,414 | 0 | 41,414 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | M | 0.12 | 41,414 | 4,970 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | S | 0.00 | 104 | 0 | 13,558 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | M | 0.00 | 4,309 | 0 | 13,662 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | M | 0.12 | 4,309 | 517 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | S | 0.00 | 1,139 | 0 | 149,320 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | M | 0.00 | 47,458 | 0 | 150,459 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | M | 0.12 | 47,458 | 5,695 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | S | 0.00 | 42 | 0 | 94,874 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | M | 0.00 | 1,731 | 0 | 94,916 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | M | 0.12 | 1,731 | 208 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | S | 0.00 | 458 | 0 | 1,044,764 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | M | 0.00 | 19,061 | 0 | 1,045,222 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | M | 0.12 | 19,061 | 2,287 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Buy | P | 5.00 | 150,000 | 750,000 | 416,481 | 266.5 K to 416.5 K (+56.29 %) |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Buy | C | 0.00 | 266,481 | 0 | 266,481 | 0 to 266.5 K |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Buy | C | 0.00 | 4,846 | 0 | 4,846 | 0 to 4.8 K |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Buy | P | 5.00 | 12,487 | 62,435 | 163,099 | 150.6 K to 163.1 K (+8.29 %) |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Buy | C | 0.00 | 150,612 | 0 | 150,612 | 0 to 150.6 K |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Buy | P | 5.00 | 137,513 | 687,565 | 1,820,933 | 1.7 M to 1.8 M (+8.17 %) |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Buy | C | 0.00 | 1,683,420 | 0 | 1,683,420 | 0 to 1.7 M |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Buy | C | 0.00 | 52,690 | 0 | 52,690 | 0 to 52.7 K |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Mow Jonathan P | Chief Executive Off ... | Option Exercise | C | 0.00 | 3,505 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Mow Jonathan P | Chief Executive Off ... | Option Exercise | C | 0.00 | 310 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Mow Jonathan P | Chief Executive Off ... | Option Exercise | M | 0.00 | 310 | 0 | 310 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Mow Jonathan P | Chief Executive Off ... | Option Exercise | M | 0.12 | 310 | 37 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Mow Jonathan P | Chief Executive Off ... | Buy | C | 0.00 | 3,505 | 0 | 48,699 | 45.2 K to 48.7 K (+7.76 %) |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Mow Jonathan P | Chief Executive Off ... | Buy | C | 0.00 | 310 | 0 | 310 | 0 to 310 |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | C | 0.00 | 226,061 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | C | 0.00 | 24,709 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | C | 0.00 | 272,107 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | C | 0.00 | 40,420 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | C | 0.00 | 13,558 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | C | 0.00 | 149,320 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | C | 0.00 | 94,874 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | C | 0.00 | 1,044,764 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | C | 0.00 | 13,609 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | C | 0.00 | 174,699 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | C | 0.00 | 4,846 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | C | 0.00 | 3,862 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | C | 0.00 | 42,530 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | C | 0.00 | 52,690 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | S | 0.00 | 994 | 0 | 40,420 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | X | 0.00 | 41,414 | 0 | 41,414 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | X | 0.12 | 41,414 | 4,970 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | S | 0.00 | 104 | 0 | 13,558 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | X | 0.00 | 4,309 | 0 | 13,662 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | X | 0.12 | 4,309 | 517 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | S | 0.00 | 1,139 | 0 | 149,320 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | X | 0.00 | 47,458 | 0 | 150,459 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | X | 0.12 | 47,458 | 5,695 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | S | 0.00 | 42 | 0 | 94,874 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | X | 0.00 | 1,731 | 0 | 94,916 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | X | 0.12 | 1,731 | 208 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | S | 0.00 | 458 | 0 | 1,044,764 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | X | 0.00 | 19,061 | 0 | 1,045,222 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Option Exercise | X | 0.12 | 19,061 | 2,287 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Buy | P | 5.00 | 150,000 | 750,000 | 416,481 | 266.5 K to 416.5 K (+56.29 %) |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Buy | C | 0.00 | 266,481 | 0 | 266,481 | 0 to 266.5 K |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Buy | C | 0.00 | 4,846 | 0 | 4,846 | 0 to 4.8 K |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Buy | P | 5.00 | 12,487 | 62,435 | 163,099 | 150.6 K to 163.1 K (+8.29 %) |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Buy | C | 0.00 | 150,612 | 0 | 150,612 | 0 to 150.6 K |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Buy | P | 5.00 | 137,513 | 687,565 | 1,820,933 | 1.7 M to 1.8 M (+8.17 %) |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Buy | C | 0.00 | 1,683,420 | 0 | 1,683,420 | 0 to 1.7 M |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Hatteras Venture Advisors III, ... | 10% Owner | Buy | C | 0.00 | 52,690 | 0 | 52,690 | 0 to 52.7 K |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | ASTRAZENECA PLC | 10% Owner | Option Exercise | C | 0.00 | 740,337 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | ASTRAZENECA PLC | 10% Owner | Option Exercise | C | 0.00 | 1,664,217 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | ASTRAZENECA PLC | 10% Owner | Option Exercise | S | 0.00 | 2,734 | 0 | 1,664,217 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | ASTRAZENECA PLC | 10% Owner | Option Exercise | X | 0.00 | 113,891 | 0 | 1,666,951 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | ASTRAZENECA PLC | 10% Owner | Option Exercise | X | 0.12 | 113,891 | 13,667 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | ASTRAZENECA PLC | 10% Owner | Buy | P | 5.00 | 600,000 | 3,000,000 | 3,004,554 | 2.4 M to 3 M (+24.95 %) |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | ASTRAZENECA PLC | 10% Owner | Buy | C | 0.00 | 2,404,554 | 0 | 2,404,554 | 0 to 2.4 M |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Arnold Susan Elizabeth | VP, Preclinical and ... | Option Exercise | C | 0.00 | 2,306 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Arnold Susan Elizabeth | VP, Preclinical and ... | Option Exercise | M | 0.00 | 103 | 0 | 2,306 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Arnold Susan Elizabeth | VP, Preclinical and ... | Option Exercise | M | 0.12 | 103 | 12 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Arnold Susan Elizabeth | VP, Preclinical and ... | Buy | C | 0.00 | 2,306 | 0 | 2,306 | 0 to 2.3 K |
Oct 17 2018 | PHAS | PhaseBio Pharmaceu ... | Mow Jonathan P | Chief Executive Off ... | Option Exercise | A | 5.00 | 220,000 | 1,100,000 | 220,000 | |
Oct 17 2018 | PHAS | PhaseBio Pharmaceu ... | Mow Jonathan P | Chief Executive Off ... | Option Exercise | A | 5.00 | 220,000 | 1,100,000 | 220,000 |